HepG2.2.15 cells transfected by HBV and HepG2 cells were used as subject cells. Cells were cultured in RPMI 1640 medium (Gibco BRL) containing 10% FBS (Gibco BRL). Negative control (NC) siRNA and XIST siRNA were purchased from Thermo Fisher Scientific, Inc. NC and miR-192 mimic were purchased from Gene Pharma (Shanghai, China). Empty vector (p-emptor vector) and lncRNA XIST over-expression vector (p-XIST) were purchased from Shanghai Jima Gene Co., Ltd. (Shanghai, China). These oligonucleotides or plasmids were transfected into HepG2.2.15 or HepG2 cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, US).

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.